Somewhat Positive Media Coverage Somewhat Unlikely to Impact Endologix (ELGX) Stock Price

News stories about Endologix (NASDAQ:ELGX) have trended somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Endologix earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 47.1911628352266 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

ELGX has been the subject of several analyst reports. Oppenheimer set a $5.00 price objective on Endologix and gave the stock a “hold” rating in a research report on Thursday, February 22nd. BidaskClub raised Endologix from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 24th. ValuEngine cut Endologix from a “sell” rating to a “strong sell” rating in a research report on Thursday, May 17th. Zacks Investment Research raised Endologix from a “sell” rating to a “hold” rating in a research report on Monday, May 7th. Finally, Stifel Nicolaus upped their price objective on Endologix from $4.50 to $5.00 and gave the stock a “hold” rating in a research report on Monday, May 21st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $4.95.

Endologix opened at $6.04 on Thursday, Marketbeat.com reports. The stock has a market cap of $492.30 million, a PE ratio of -12.58 and a beta of 0.44. Endologix has a 1 year low of $3.75 and a 1 year high of $6.50. The company has a quick ratio of 1.37, a current ratio of 2.13 and a debt-to-equity ratio of 3.58.

Endologix (NASDAQ:ELGX) last released its quarterly earnings data on Wednesday, May 2nd. The medical instruments supplier reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. Endologix had a negative return on equity of 47.01% and a negative net margin of 35.86%. The business had revenue of $42.28 million during the quarter, compared to analysts’ expectations of $41.14 million. During the same period in the prior year, the firm posted ($0.18) EPS. The business’s quarterly revenue was down .8% compared to the same quarter last year. research analysts forecast that Endologix will post -0.7 earnings per share for the current year.

Endologix Company Profile

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

Insider Buying and Selling by Quarter for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Employees Retirement System of Texas Sells 14,000 Shares of KLA-Tencor Corp
Employees Retirement System of Texas Sells 14,000 Shares of KLA-Tencor Corp
Blount International  Earns Daily Media Sentiment Score of 0.30
Blount International Earns Daily Media Sentiment Score of 0.30
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Endologix  Stock Price
Somewhat Positive Media Coverage Somewhat Unlikely to Impact Endologix Stock Price
Lincoln Electric  Given Consensus Rating of “Buy” by Analysts
Lincoln Electric Given Consensus Rating of “Buy” by Analysts
$25.34 Billion in Sales Expected for Express Scripts Holding Co  This Quarter
$25.34 Billion in Sales Expected for Express Scripts Holding Co This Quarter
212,670 Shares in Blackrock Muniyield Insured Fund Inc.  Purchased by Fiera Capital Corp
212,670 Shares in Blackrock Muniyield Insured Fund Inc. Purchased by Fiera Capital Corp


Leave a Reply

© 2006-2018 Ticker Report. Google+.